Agfa introduces modular digital solutions
A modular family of product combinations launched today by Agfa is designed to give customers of all types affordable access to computed radiography, printer, and networking technology. Dubbed initia, the offerings are built around the company's CR 1000
A modular family of product combinations launched today by Agfa is designed to give customers of all types affordable access to computed radiography, printer, and networking technology. Dubbed initia, the offerings are built around the company's CR 1000 digitizer, either of two midtier laser printers, and its entry-level PACS.
The products can be grouped to provide cost-effective solutions to digital problems to customers ranging from clinics, private radiologists, and imaging centers to small- and medium-sized hospitals, according to the company.
The modular approach, with its varied offerings, will be commercially available in the first quarter of 2003. Agfa strategists will seek to balance the current needs and budget constraints of customers with the flexibility to allow customers to build on initial investments with expanded equipment as those needs change.
The simplest solution is a CR 1000 digitizer, a single PC, and network switch, aimed at customers who already have a printer. At the high end of the offering is a combination CR 1000-IMPAX Basix, featuring a digitizer, PC, network switch, and PACS for small- and medium-sized facilities.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.
